BMO Capital analyst Etzer Darout initiated coverage of BioNTech with an Outperform rating and $127 price target. BioNTech realized massive growth during the COVID-19 pandemic, but the stock has pulled back significantly on COVID-19 uncertainties, the analyst tells investors in a research note. The firm believes COVID-19 overshadows an emerging oncology pipeline that can deliver meaningful share upside on clinical de-risking of mid and late-stage programs in 2024 and 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNTX:
- BioNTech price target raised to $171 from $168 at Canaccord
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
- BioNTech, Autolus Therapeutics announce strategic alliance
- Lost Money in MBLY, BNTX, DADA, INSP or ON? Class Action Suits Filed, Seeking Recovery
- BioNTech and Duality announce FDA Fast track designation for BNT325/DB-1305
